Abstract
Alzheimer’s disease (AD), a neuro-degenerative disease that primarily affects the elderly, is a worldwide phenomenon. Loss of memory, cognitive decline, behavioural changes, and many other signs are used to classify it. Various hypotheses that may contribute to Alzheimer’s disease have been found during decades of survey, including tau theory, the amyloid theory, the cholinergic hypothesis, and the oxidative stress hypothesis. According to some theories, the two leading causes of AD are the accumulation of amyloid beta plaque and development of NFTs in the brain. The hippocampus and cerebral cortex are the primary sites where amyloid beta plaques gather in the body. NFT formation in the brain impairs the brain’s neurons’ potential of signalling. According to the age at which it manifests in a person, there are two subtypes of AD: ‘LOAD (Late Onset Alzheimer’s Disease)’ and ‘EOAD (Early Onset Alzheimer’s Disease)’. Long-term research into AD treatment has resulted in the introduction of some medications that provided symptomatic relief to patients but did not alter the disease’s pathophysiology, like cholinesterase inhibitors, inhibitors of tau aggregation, and monoclonal antibodies to Aβ aggregation. Even though the medications did not halt the progression of AD, researchers did not discontinue their work, which lead to the introduction of gene therapy — a recently created cutting-edge method of delivering genes to target sites where they can express the intended functionalities. Viral or non-viral vectors could be used to deliver the gene, each with advantages and limitations of their own. Gene therapy is proven to be a potential disease-modifying treatment for AD. This article discusses about gene therapy, its merits and demerits and the various ways of gene delivery. Additionally, it focuses on AD as the target for treatment through gene therapy, the pathophysiology of AD, and the multiple targets for gene therapy in the treatment of AD.
Similar content being viewed by others
Data availability
No datasets used.
References
Alves S, Fol R, Cartier N (2016) Gene therapy strategies for Alzheimer’s disease: an overview. In: In: Human Gene Therapy (Vol. 27, Issue 2, pp. 100–107). Mary Ann Liebert Inc. https://doi.org/10.1089/hum.2016.017
Athar T, al Balushi K, Khan SA (2021) Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. In: Molecular Biology Reports (Vol. 48, Issue 7, pp. 5629–5645). Springer Science and Business Media B.V. https://doi.org/10.1007/s11033-021-06512-9
Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C (n.d.). Early-onset Alzheimer’s disease: what is missing in research? https://doi.org/10.1007/s11910-020-01090-y/Published
Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C (2021) Early-onset Alzheimer’s disease: what is missing in research? Curr Neuro Neurosci Rep 21(2):4. https://doi.org/10.1007/s11910-020-01090-y
Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, Pappolla MA, Sambamurti K, Alzheimer C, Author R (2015). Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer’s disease HHS Public Access Author manuscript. In Curr Alzheimer Res (Vol. 12, Issue 1).
Baum C, Düllmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C (2003). Side effects of retroviral gene transfer into hematopoietic stem cells. In Blood (Vol. 101, Issue 6, pp. 2099–2114). https://doi.org/10.1182/blood-2002-07-2314
Belloy ME, Napolioni V, Greicius MD (2019). A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. In: Neuron (Vol. 101, Issue 5, pp. 820–838). Cell Press. https://doi.org/10.1016/j.neuron.2019.01.056
Bondi MW, Edmonds EC, Salmon DP (2017) Alzheimer’s disease: past, present, and future. In: Journal of the International Neuropsychological Society (Vol. 23, Issues 9-10 Special Issue, pp. 818–831). Cambridge University Press. https://doi.org/10.1017/S135561771700100X
Briggs R, Kennelly SP, O'Neill D (2016) Drug treatments in Alzheimer’s disease. Clinical medicine 16(3):247
Bulaklak K, Gersbach CA (2020). The once and future gene therapy. In: Nature Communications (Vol. 11, Issue 1). Nature Research. https://doi.org/10.1038/s41467-020-19505-2
Burrell M, Henderson SJ, Ravnefjord A, Schweikart F, Fowler SB, Witt S, Hansson KM, Webster CI (2016) Neprilysin inhibits coagulation through proteolytic inactivation of fibrinogen. PLoS ONE 11(7). https://doi.org/10.1371/journal.pone.0158114
Butt, M. H., Zaman, M., Ahmad, A., Khan, R., Mallhi, T. H., Hasan, M. M., Khan, Y. H., Hafeez, S., Massoud, E. E. S., Rahman, M. H., & Cavalu, S. (2022). Appraisal for the potential of viral and nonviral vectors in gene therapy: a review. In: Genes (Vol. 13, Issue 8). MDPI. https://doi.org/10.3390/genes13081370
Butterfield DA, Johnson LA (2020) APOE in Alzheimer’s disease and neurodegeneration. In: Neurobiology of Disease, vol 139. Academic Press Inc. https://doi.org/10.1016/j.nbd.2020.104847
Castle MJ, Baltanás FC, Kovacs I, Nagahara AH, Barba D, Tuszynski MH (2020) Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer’s disease identifies a need for improved vector delivery. Human Gene Therapy 31(7–8):415–422. https://doi.org/10.1089/hum.2019.367
Chatterjee K, Lakdawala S, Quadir SS, Puri D, Mishra DK, Joshi G, Sharma S, Choudhary D (2023) siRNA-based novel therapeutic strategies to improve effectiveness of antivirals: an insight. AAPS PharmSciTech 24(6):170. https://doi.org/10.1208/s12249-023-02629-1
Chen W, Hu Y, Ju D (2020a) Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharmaceutica Sinica B 10(8):1347–1359. https://doi.org/10.1016/j.apsb.2020.01.015
Chen W, Hu Y, Ju D (2020b) Gene therapy for neurodegenerative disorders: advances, insights and prospects. In: Acta Pharmaceutica Sinica B (Vol. 10, Issue 8, pp. 1347–1359). Chinese Academy of Medical Sciences. https://doi.org/10.1016/j.apsb.2020.01.015
Chen Y, Strickland MR, Soranno A, Holtzman DM (2021) Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. In: Neuron (Vol. 109, Issue 2, pp. 205–221). Cell Press. https://doi.org/10.1016/j.neuron.2020.10.008
Choi SS, Lee S-R, Kim SU, Lee HJ (2014) Alzheimer’s disease and stem cell therapy. Experimental Neurobiology 23(1):45–52. https://doi.org/10.5607/en.2014.23.1.45
Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F, Tasciotti E (2016) The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. In: Nanomedicine (Vol. 11, Issue 1, pp. 81–100). Future Medicine Ltd. https://doi.org/10.2217/nnm.15.188
Dziaková A, Valenčáková A, Hatalová E, Kalinová J (2016) The use of viral vectors in gene transfer therapy. Int J Pharmaceut Sci Drug Res 8(03). https://doi.org/10.25004/ijpsdr.2016.080301
Ertl HCJ (2022) Immunogenicity and toxicity of AAV gene therapy. In: Frontiers in Immunology (Vol. 13), Frontiers Media S.A. https://doi.org/10.3389/fimmu.2022.975803
Fahnestock M, Shekari A (2019) ProNGF and neurodegeneration in Alzheimer’s disease. Front Neurosci 13:129. https://doi.org/10.3389/fnins.2019.00129
Fattah S, Rehn M, Reierth E, Wisborg T (2013) Systematic literature review of templates for reporting prehospital major incident medical management BMJ Open 3(8):e002658. https://doi.org/10.1136/bmjopen-2013-002658
Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P (2005) Vectors and delivery systems in gene therapy. Med Sci Monit 11(4):110–121
Gauthier S, Leuzy A, Racine E, Rosa-Neto P (2013). Diagnosis and management of Alzheimer’s disease: past, present and future ethical issues. In Progress in Neurobiology (Vol. 110, pp. 102–113). https://doi.org/10.1016/j.pneurobio.2013.01.003
Gene Therapy and Cell Transplantation. (n.d.).
Gene Therapy as an Alternative. (n.d.).
Giulimondi F, Digiacomo L, Pozzi D, Palchetti S, Vulpis E, Capriotti AL, Chiozzi RZ, Laganà A, Amenitsch H, Masuelli L, Mahmoudi M, Screpanti I, Zingoni A, Caracciolo G (2019) Interplay of protein corona and immune cells controls blood residency of liposomes. Nature. Communications 10(1). https://doi.org/10.1038/s41467-019-11642-7
Gonçalves GAR, Paiva RDMA (2017) Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo) 15(3):369–375. https://doi.org/10.1590/S1679-45082017RB4024
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302(23):2557–2564. https://doi.org/10.1001/jama.2009.1866
Grimm MOW, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T (2013) Neprilysin and Aβ clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer’s disease. In: Frontiers in Aging Neuroscience. (Vol. 5, Issue DEC), Frontiers Media SA. https://doi.org/10.3389/fnagi.2013.00098
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian ZS (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141(7):1917–1933. https://doi.org/10.1093/brain/awy132
Holthoff VA, Ferris S, Ihl R, Robert P, Winblad B, Gauthier S, Sternberg K, Tennigkeit F (2011) Validation of the relevant outcome scale for Alzheimer’s disease: a novel multidomain assessment for daily medical practice. Alzheimer’s Research and Therapy 3(5). https://doi.org/10.1186/alzrt89
Jafarlou M (2016). An overview of the history, applications, advantages, disadvantages and prospects of gene therapy. https://www.researchgate.net/publication/304988303
Katal PS (n.d.). Human gene therapy
Klein C, Roussel G, Brun S, Rusu C, Patte-Mensah C, Maitre M, Mensah-Nyagan AG (2018) 5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer’s disease. Acta Neuropatholog Commun 6(1):136. https://doi.org/10.1186/s40478-018-0640-z
Kondo T, Banno H, Okunomiya T, Amino Y, Endo K, Nakakura A, Uozumi R, Kinoshita A, Tada H, Morita S, Ishikawa H, Shindo A, Yasuda K, Taruno Y, Maki T, Suehiro T, Mori K, Ikeda M, Fujita K et al (2021) Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations. BMJ Open 11(6). https://doi.org/10.1136/bmjopen-2021-051343
Lane-Donovan C, Herz J (2017) ApoE, ApoE receptors, and the synapse in Alzheimer’s disease. In: Trends in Endocrinology and Metabolism. (Vol. 28, Issue 4, pp. 273–284). Elsevier Inc. https://doi.org/10.1016/j.tem.2016.12.001
Lanfranco MF, Ng CA, Rebeck GW (2020) ApoE lipidation as a therapeutic target in Alzheimer’s disease. Int J Molecular Sci 21(17):1–19. https://doi.org/10.3390/ijms21176336
Lee E, Son H (n.d.). Adult hippocampal neurogenesis and related neurotrophic factors. http://bmbreports.org
Lee E-G, Son H (2009) Adult hippocampal neurogenesis and related neurotrophic factors. BMB Reports 42(5):239–244. https://doi.org/10.5483/BMBRep.2009.42.5.239
Li Y, Wang Y, Wang J, Chong KY, Xu J, Liu Z, Shan C (2020) Expression of neprilysin in skeletal muscle by ultrasound-mediated gene transfer (sonoporation) reduces amyloid burden for AD. Mole Therapy - Meth Clin Develop 17:300–308. https://doi.org/10.1016/j.omtm.2019.12.012
Lim CS, Han JS (2018) The antioxidant xanthorrhizol prevents amyloid-β-induced oxidative modification and inactivation of neprilysin. Biosci Rep 38(1). https://doi.org/10.1042/BSR20171611
Liu PP, Xie Y, Meng XY, Kang JS (2019) History and progress of hypotheses and clinical trials for Alzheimer’s disease. In: Signal Transduction and Targeted Therapy (Vol. 4, Issue 1). Springer Nature. https://doi.org/10.1038/s41392-019-0063-8
Loera‐Valencia R, Piras A, Ismail MAM, Manchanda S, Eyjolfsdottir H, Saido TC, Nilsson P (2018) Targeting alzheimer's disease with gene and cell therapies. J Intern Med 284(1):2–36. https://doi.org/10.1111/joim.12759
Lukashev AN, Zamyatnin AA (2016) Viral vectors for gene therapy: current state and clinical perspectives. In: Biochemistry (Moscow) (Vol. 81, Issue 7, pp. 700–708). Maik Nauka Publishing / Springer SBM. https://doi.org/10.1134/S0006297916070063
Marr R, Hafez D (2014) Amyloid beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance. Frontiers in Aging. Neuroscience 6(JUL). https://doi.org/10.3389/fnagi.2014.00187
Mcconnell 1999 (n.d.).
Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G (2016) Therapies for prevention and treatment of Alzheimer’s disease. Biomed Res Int 2016:1–17. https://doi.org/10.1155/2016/2589276
Milne R (2020) The rare and the common: scale and the genetic imaginary in Alzheimer’s disease drug development. New Genetics Soc 39(1):101–126. https://doi.org/10.1080/14636778.2019.1637718
Misra S (2013) Human gene therapy : a brief overview of the genetic revolution. JAPI 61:127–133
Mücke MM, FongS, FosterGR, Lillicrap D, Miesbach W, Zeuzem S (2023). Adeno-associated viruses for gene therapy – clinical implications and liver related complications, a guide for hepatologists. J Hepatol. https://doi.org/10.1016/j.jhep.2023.10.029
Nalivaeva NN, Turner AJ (2019) Targeting amyloid clearance in Alzheimer’s disease as a therapeutic strategy. Br J Pharmacol 176:3447–3463. https://doi.org/10.1111/bph.v176.18/issuetoc
Nalivaeva NN, Zhuravin IA, Turner AJ (2020). Neprilysin expression and functions in development, ageing and disease. Mechanisms of Ageing and Development, 192. https://doi.org/10.1016/j.mad.2020.111363
Naso MF, Tomkowicz B, Perry WL, Strohl WR (2017) Adeno-associated virus (AAV) as a vector for gene therapy. In: BioDrugs (Vol. 31, Issue 4, pp. 317–334). Springer International Publishing. https://doi.org/10.1007/s40259-017-0234-5
Nayerossadat N, Ali P, Maedeh T (2012) Viral and nonviral delivery systems for gene delivery. Advanced Biomedical Research 1(1):27. https://doi.org/10.4103/2277-9175.98152
Nilsson P, Iwata N, Muramatsu SI, Tjernberg LO, Winblad B, Saido TC (2010) Gene therapy in Alzheimer’s disease - potential for disease modification. J Cell Mole Med 14(4):741–757. https://doi.org/10.1111/j.1582-4934.2010.01038.x
Numakawa T, Odaka H (2021). Brain-derived neurotrophic factor signaling in the pathophysiology of Alzheimer’s disease: beneficial effects of flavonoids for neuroprotection. In: International Journal of Molecular Sciences (Vol. 22, Issue 11). MDPI. https://doi.org/10.3390/ijms22115719
Nunan J, Small DH (2000) Regulation of APP cleavage by α-, β- and γ-secretases. In: FEBS Letters. (Vol. 483, Issue 1, pp. 6–10). Elsevier. https://doi.org/10.1016/S0014-5793(00)02076-7
Paul A, Collins MG, Lee HY (2022) Gene therapy: the next-generation therapeutics and their delivery approaches for neurological disorders. In: Frontiers in Genome Editing (Vol. 4), Frontiers Media S.A. https://doi.org/10.3389/fgeed.2022.899209
Reitz C (2015). Genetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities. In: Expert Review of Molecular Diagnostics (Vol. 15, Issue 3, pp. 339–348). Expert Reviews Ltd. https://doi.org/10.1586/14737159.2015.1002469
Robinson M, Lee BY, Hane FT (2017). Recent progress in Alzheimer’s disease research, part 2: genetics and epidemiology. In: Journal of Alzheimer’s disease : JAD (Vol. 57, Issue 2, pp. 317–330). https://doi.org/10.3233/JAD-161149
Rofo F, Yilmaz CU, Metzendorf N, Gustavsson T, Beretta C, Erlandsson A, Sehlin D, Syvänen S, Nilsson P, Hultqvist G (2020) Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain. Theranostics 11(2):789–804. https://doi.org/10.7150/thno.50263
Sakai M, Ueda S, Daito T, Asada-Utsugi M, Komatsu Y, Kinoshita A, Maki T, Kuzuya A, Takahashi R, Makino A, Tomonaga K (2018) Degradation of amyloid β peptide by neprilysin expressed from Borna disease virus vector. Microbiol Immun 62(7):467–472. https://doi.org/10.1111/1348-0421.12602
Scheltens P, de Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM (2021) Alzheimer’s disease. In: The Lancet (Vol. 397, Issue 10284, pp. 1577–1590), Elsevier B.V. https://doi.org/10.1016/S0140-6736(20)32205-4
Selkirk SM (2004). Gene therapy in clinical medicine. In: Postgraduate Medical Journal (Vol. 80, Issue 948, pp. 560–570). https://doi.org/10.1136/pgmj.2003.017764
Sharma S, Behl T, Kumar A, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Bungau S (2021) Targeting endothelin in Alzheimer’s disease: a promising therapeutic approach. In: BioMed Research International (Vol. 2021), Hindawi Limited. https://doi.org/10.1155/2021/7396580
Singh RK (2020) Recent trends in the management of Alzheimer’s disease: current therapeutic options and drug repurposing approaches. Curr Neuropharmacol 18(9):868–882. https://doi.org/10.2174/1570159x18666200128121920
Sitnik JL, Francis C, Hens K, Huybrechts R, Wolfner MF, Callaerts P (2014) Neprilysins: an evolutionarily conserved family of metalloproteases that play important roles in reproduction in Drosophila. Genetics 196(3):781–797. https://doi.org/10.1534/genetics.113.160945
Sivagourounadin K, Ravichandran M, Rajendran P (2021) National guidelines for gene therapy product (2019): a road-map to gene therapy products development and clinical trials. In: Perspectives in Clinical Research (Vol. 12, Issue 3, pp. 118–125). Wolters Kluwer Medknow Publications. https://doi.org/10.4103/picr.PICR_189_20
Slade N (2001) Viral vectors in gene therapy. Periodicum Biologorum 103(2):139–143. https://doi.org/10.3390/diseases6020042
Takamatsu K, Ikeda T, Haruta M, Matsumura K, Ogi Y, Nakagata N, Uchino M, Ando Y, Nishimura Y, Senju S (2014) Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2. Stem Cell Research 13(3):442–453. https://doi.org/10.1016/j.scr.2014.10.001
Trapani I (2019) Adeno-associated viral vectors as a tool for large gene delivery to the retina. Genes 10(4). https://doi.org/10.3390/genes10040287
Tuszynski MH, Yang JH, Barba D, Hoi-Sang U, Bakay RAE, Pay MM, Masliah E, Conner JM, Kobalka P, Roy S, Nagahara AH (2015) Nerve growth factor gene therapy activation of neuronal responses in Alzheimer disease. JAMA Neurology 72(10):1139–1147. https://doi.org/10.1001/jamaneurol.2015.1807
Walther W, Stein U (2000) Viral vectors for gene transfer. Drugs 60(2):249–271. https://doi.org/10.2165/00003495-200060020-00002
Wierenga CE, Hays CC, Zlatar ZZ (2014). Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer’s disease. In Journal of Alzheimer’s Disease (Vol. 42, pp. S411–S419). IOS Press. https://doi.org/10.3233/JAD-141467
Wischik CM, Harrington CR, Storey JMD (2014) Tau-aggregation inhibitor therapy for Alzheimer’s disease. In: Biochemical Pharmacology (Vol. 88, Issue 4, pp. 529–539). Elsevier Inc. https://doi.org/10.1016/j.bcp.2013.12.008
Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H, Bian Z, Chen X, Lu A, Yang Z (2019). Review of current strategies for delivering Alzheimer’s disease drugs across the blood-brain barrier. In: International Journal of Molecular Sciences (Vol. 20, Issue 2). MDPI AG. https://doi.org/10.3390/ijms20020381
Wu P, Chen H, Jin R, Weng T, Ho JK, You C, Zhang L, Wang X, Han C (2018) Non-viral gene delivery systems for tissue repair and regeneration. In: Journal of Translational Medicine (Vol. 16, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12967-018-1402-1
Xiao Q, Guo D, Chen S (2019) Application of CRISPR/Cas9-based gene editing in HIV-1/AIDS therapy. In: Frontiers in Cellular and Infection Microbiology (Vol. 9, Issue MAR), Frontiers Media S.A. https://doi.org/10.3389/fcimb.2019.00069
Yang A, Kantor B, Chiba-Falek O (2021). Apoe: the new frontier in the development of a therapeutic target towards precision medicine in late-onset alzheimer’s. In: International Journal of Molecular Sciences (Vol. 22, Issue 3, pp. 1–15). MDPI AG. https://doi.org/10.3390/ijms22031244
Yiannopoulou KG, Papageorgiou SG (2013) Current and future treatments for Alzheimer’s disease. Therapeutic advances in neurological disorders 6(1):19–33. https://doi.org/10.1177/1756285612461679
Zeng Y, Li Y, Shen H, Lin N, Zhang J (2021) Tripchlorolide attenuates β-amyloid generation by inducing NEP activity in N2a/APP695 cells. Translational Neuroscience 12(1):301–308. https://doi.org/10.1515/tnsci-2020-0178
Zhao N, Liu CC, Qiao W, Bu G (2018) Apolipoprotein E, receptors, and modulation of Alzheimer’s disease. In: Biological Psychiatry (Vol. 83, Issue 4, pp. 347–357), Elsevier USA. https://doi.org/10.1016/j.biopsych.2017.03.003
Zhou L, Liu J, Dong D, Wei C, Wang R (2017). Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer’s disease. In: Am J Transl Res (Vol. 9, Issue 1). www.ajtr.org
Author information
Authors and Affiliations
Contributions
Vanshika Doshi and Garima Joshi collected the data and wrote the manuscript. Sanjay Sharma and Deepak Choudhary draw and design the figures and review the manuscript. The authors confirm that no paper mill and artificial intelligence was used.
Corresponding authors
Ethics declarations
Ethical approval
No ethical approval is needed. No animal study performed.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Doshi, V., Joshi, G., Sharma, S. et al. Gene therapy: an alternative to treat Alzheimer’s disease. Naunyn-Schmiedeberg's Arch Pharmacol 397, 3675–3693 (2024). https://doi.org/10.1007/s00210-023-02873-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-023-02873-z